238 related articles for article (PubMed ID: 22541618)
21. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
Castro M; Zangrilli J; Wechsler ME; Bateman ED; Brusselle GG; Bardin P; Murphy K; Maspero JF; O'Brien C; Korn S
Lancet Respir Med; 2015 May; 3(5):355-66. PubMed ID: 25736990
[TBL] [Abstract][Full Text] [Related]
22. The consequences of not having eosinophils.
Gleich GJ; Klion AD; Lee JJ; Weller PF
Allergy; 2013 Jul; 68(7):829-35. PubMed ID: 23742015
[TBL] [Abstract][Full Text] [Related]
23. Novel targeted therapies for eosinophilic disorders.
Wechsler ME; Fulkerson PC; Bochner BS; Gauvreau GM; Gleich GJ; Henkel T; Kolbeck R; Mathur SK; Ortega H; Patel J; Prussin C; Renzi P; Rothenberg ME; Roufosse F; Simon D; Simon HU; Wardlaw A; Weller PF; Klion AD
J Allergy Clin Immunol; 2012 Sep; 130(3):563-71. PubMed ID: 22935585
[TBL] [Abstract][Full Text] [Related]
24. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
Bel EH; Wenzel SE; Thompson PJ; Prazma CM; Keene ON; Yancey SW; Ortega HG; Pavord ID;
N Engl J Med; 2014 Sep; 371(13):1189-97. PubMed ID: 25199060
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
[TBL] [Abstract][Full Text] [Related]
26. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
27. Tailored therapy for severe asthma.
Menzella F; Lusuardi M; Galeone C; Zucchi L
Multidiscip Respir Med; 2015; 10(1):1. PubMed ID: 25671117
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.
Arron JR; Choy DF; Scheerens H; Matthews JG
Ann Am Thorac Soc; 2013 Dec; 10 Suppl():S206-13. PubMed ID: 24313774
[TBL] [Abstract][Full Text] [Related]
30. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
31. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma.
Ortega H; Li H; Suruki R; Albers F; Gordon D; Yancey S
Ann Am Thorac Soc; 2014 Sep; 11(7):1011-7. PubMed ID: 24983709
[TBL] [Abstract][Full Text] [Related]
32. Reslizumab: First Global Approval.
Markham A
Drugs; 2016 May; 76(8):907-11. PubMed ID: 27125787
[TBL] [Abstract][Full Text] [Related]
33. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
34. Changing roles of eosinophils in health and disease.
Furuta GT; Atkins FD; Lee NA; Lee JJ
Ann Allergy Asthma Immunol; 2014 Jul; 113(1):3-8. PubMed ID: 24795292
[TBL] [Abstract][Full Text] [Related]
35. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.
Liu Y; Zhang S; Li DW; Jiang SJ
PLoS One; 2013; 8(3):e59872. PubMed ID: 23544105
[TBL] [Abstract][Full Text] [Related]
37. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
38. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
Bjermer L; Lemiere C; Maspero J; Weiss S; Zangrilli J; Germinaro M
Chest; 2016 Oct; 150(4):789-798. PubMed ID: 27056586
[TBL] [Abstract][Full Text] [Related]
39. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
Corren J; Weinstein S; Janka L; Zangrilli J; Garin M
Chest; 2016 Oct; 150(4):799-810. PubMed ID: 27018175
[TBL] [Abstract][Full Text] [Related]
40. Mepolizumab for eosinophilic severe asthma: recent studies.
Robinson DS; Kariyawasam HH
Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
